{"id":"NCT00769314","sponsor":"Valerio Therapeutics","briefTitle":"Phase 3 Clinical Study for the Treatment of Cold Sore","officialTitle":"A Randomised, Double-Blind, Single Dose, One-Day Early Administration, Multicentre Study Comparing the Efficacy and Safety of Acyclovir Lauriad® 50 mg Muco-adhesive Buccal Tablet to Matching Placebo, in the Treatment of Herpes Labialis in Immunocompetent Patients.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05","primaryCompletion":"2008-11","completion":"2009-08","firstPosted":"2008-10-09","resultsPosted":"2012-12-21","lastUpdate":"2012-12-21"},"enrollment":1727,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Herpes Labialis"],"interventions":[{"type":"DRUG","name":"Acyclovir Lauriad","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"To demonstrate the efficacy of a single dose of acyclovir Lauriad® 50mg muco-adhesive buccal tablet versus a single dose of matching placebo on the primary vesicular lesion of cold sore.","primaryOutcome":{"measure":"Time to Healing (TTH) of Vesicular Primary Lesion","timeFrame":"Assessed from time of treatment initiation through Day 14","effectByArm":[{"arm":"Acyclovir Lauriad Group","deltaMin":7,"sd":0.18},{"arm":"Placebo Group","deltaMin":7.32,"sd":0.18}],"pValues":[{"comp":"OG000 vs OG001","p":"0.015"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":21},"locations":{"siteCount":53,"countries":["United States","Australia","Czechia","France","Germany","Poland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":378},"commonTop":["headache","Application Site Pain","Nasopharyngitis","nausea"]}}